Abstract
Background: Rheumatoid arthritis (RA) is an immune mediated joint-based chronic inflammatory disorder recognized by joint inflammation, destruction, pain and remission. Currently, numerous pharmacotherapeutic strategies have gained immense popularity in RA therapy and improving the patient life.
Methods: Besides, it exhibits numerous drawbacks such as requirement of high dose of drugs, unavoidable adverse effects and diseases remission. Thus, use of currently available pharmacotherapeutics employing conventional formulations can only provide therapeutic effects to a certain extent.
Results: Recent advancements in nanotechnology-based lipidic vesicular nanocarriers have led provided improved efficacy and safety for the anti-rheumatic drugs. These include liposomes, stealth liposomes, ethosomes, transfersomes, etc., which have shown their potential to improve the therapeutic efficacy of antirheumatic drugs with lesser toxicity. Although the results of animal models for use of lipid vesicular nanocarriers for drug targeting in RA have been found to be highly promising, but lack of sufficient data in a clinical setup are still evident to demonstrate their practical utility in patient populations. In this regard, considerable research studies are required for evaluating the efficacy and safety of the aforementioned nanocarriers in RA through clinical studies.
Conclusion: The present review, therefore, covers the brief pathophysiology of RA, current medication and their challenges in RA therapy. Besides, an extensive account on recent advancements in novel lipid vesicular nanocarriers in RA therapy has also been addressed with special emphasis on the patent literature too.
Keywords: Immune disorders, rheumatoid arthritis, liposomes, ethosomes, transferosomes, high permeable vesicles.
Graphical Abstract
Recent Patents on Anti-Infective Drug Discovery
Title:Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis
Volume: 11 Issue: 1
Author(s): Mahfoozur Rahman, Sarwar Beg, Gajanand Sharma, Sumant Saini, Rehan A. Rub, Preeti Aneja, Firoz Anwar, Mohammad A. Alam and Vikas Kumar
Affiliation:
Keywords: Immune disorders, rheumatoid arthritis, liposomes, ethosomes, transferosomes, high permeable vesicles.
Abstract: Background: Rheumatoid arthritis (RA) is an immune mediated joint-based chronic inflammatory disorder recognized by joint inflammation, destruction, pain and remission. Currently, numerous pharmacotherapeutic strategies have gained immense popularity in RA therapy and improving the patient life.
Methods: Besides, it exhibits numerous drawbacks such as requirement of high dose of drugs, unavoidable adverse effects and diseases remission. Thus, use of currently available pharmacotherapeutics employing conventional formulations can only provide therapeutic effects to a certain extent.
Results: Recent advancements in nanotechnology-based lipidic vesicular nanocarriers have led provided improved efficacy and safety for the anti-rheumatic drugs. These include liposomes, stealth liposomes, ethosomes, transfersomes, etc., which have shown their potential to improve the therapeutic efficacy of antirheumatic drugs with lesser toxicity. Although the results of animal models for use of lipid vesicular nanocarriers for drug targeting in RA have been found to be highly promising, but lack of sufficient data in a clinical setup are still evident to demonstrate their practical utility in patient populations. In this regard, considerable research studies are required for evaluating the efficacy and safety of the aforementioned nanocarriers in RA through clinical studies.
Conclusion: The present review, therefore, covers the brief pathophysiology of RA, current medication and their challenges in RA therapy. Besides, an extensive account on recent advancements in novel lipid vesicular nanocarriers in RA therapy has also been addressed with special emphasis on the patent literature too.
Export Options
About this article
Cite this article as:
Rahman Mahfoozur, Beg Sarwar, Sharma Gajanand, Saini Sumant, A. Rub Rehan, Aneja Preeti, Anwar Firoz, A. Alam Mohammad and Kumar Vikas, Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis, Recent Patents on Anti-Infective Drug Discovery 2016; 11 (1) . https://dx.doi.org/10.2174/1574891X1101160511195513
DOI https://dx.doi.org/10.2174/1574891X1101160511195513 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Editorial
Current Enzyme Inhibition Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets From Raynaud’s Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach
Current Rheumatology Reviews PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism subject Index To Volume 4
Combinatorial Chemistry & High Throughput Screening The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety Animal Models of Lung Fibrosis
Current Respiratory Medicine Reviews Human-Derived Organ-on-a-Chip for Personalized Drug Development
Current Pharmaceutical Design Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview
Current Drug Targets Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options
Current Topics in Medicinal Chemistry Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
Current Respiratory Medicine Reviews Hepatocyte Growth Factor in Normal and Diseased Bone and Joint Tissues
Current Rheumatology Reviews